Marksans Pharma Limited (BOM:524404)

Market Cap	113.36B
Revenue (ttm)	26.23B
Net Income (ttm)	3.81B
Shares Out	n/a
EPS (ttm)	8.40
PE Ratio	29.79
Forward PE	23.29
Dividend	0.60 (0.24%)
Ex-Dividend Date	Sep 17, 2024

Volume	44,404
Average Volume	112,864
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	158.25 - 358.50
Beta	n/a
RSI	51.01
Earnings Date	May 30, 2025

About Marksans Pharma

Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, upper respiratory, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamin...

• Industry: Pharmaceutical Preparations
• Founded: 1992
• Employees: 1,141
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 524404

Financial Performance

In 2024, Marksans Pharma's revenue was 26.23 billion, an increase of 20.46% compared to the previous year's 21.77 billion. Earnings were 3.81 billion, an increase of 21.32%.